<DOC>
	<DOCNO>NCT02697838</DOCNO>
	<brief_summary>A single arm study : Apatinib plus paclitaxel revers treatment advance gastric cancer paclitaxel-resistant .</brief_summary>
	<brief_title>Clinical Trial Apatinib Reverses Chemotherapy-Resistance Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description>This trial investigate efficacy safety apatinib plus paclitaxel , treatment option patient advance gastric cancer paclitaxel-resistant .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Age : 18 year old ; 2 . Histologically confirm advanced metastatic adenocarcinoma gastric cancer ( AGC ) , include adenocarcinoma gastroesophageal junction ; 3 . At least one measurable evaluable disease base response evaluation criterion solid tumor ( RECIST v1.1 ) ; 4 . The patient Prior PaclitaxelResistant ; 5 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 ; 6 . An expected survival ≥ 3 month ; 7 . Duration last therapy 6 week nitroso mitomycin , More 4 week cytotoxic agent , operation radiotherapy ; 8 . Major organ function meet follow criterion ; ( 1 ) For result blood routine test : 1 . Hemoglobin ( HB ) ≥ 80g / L , 2 . ANC ≥ 1.5 × 109 / L , 3 . PLT ≥ 75 × 109 / L , ( 2 ) For result biochemical test : 1 . BLT ≤ 1.25 time upper limit normal ( ULN ) , 2 . ALT AST ≤ 2.5 × ULN , liver metastasis , , ALT AST≤ 5 × ULN , 3 . Serum Cr≤1ULN , Endogenous creatinine clearance rate ＞50ml/min ; 9 . Pregnancy test ( serum urine ) perform woman childbearing age within 7 day enrolment test result must negative . They shall take appropriate method contraception study 8th week post last administration study drug . For men , ( previous surgical sterilization accept ) , shall agree take appropriate method contraception study 8th week post last administration study drug ; 10 . Patient voluntarily join study sign Informed Consent Form study . 1 . History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix ; 2 . Confirmed apatinib and/or accessory allergy ; 3 . Subjects poorcontrolled arterial hypertension ( systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mm Hg ) despite standard medical management ; 4 . Serious cardiovascular disease : Ⅱlevel myocardial ischemia myocardial infarction , arrhythmia ( include QT interval prolongation , man ≥ 450 m , woman ≥ 470 m ) ; III ~ IV level cardiac function insufficiency , echocardiography show left ventricular ejection fraction ( LVEF &lt; 50 % ) ; 5 . Patients positive urinary protein ( urine protein detection 2 , 24 hour urine protein &gt; 1.0g ) ; 6 . Factors could effect oral medication ( inability swallow , chronic diarrhea intestinal obstruction ) ; 7 . Subjects high gastrointestinal bleeding risk , include follow condition : local active ulcer lesion positive fecal occult blood test ( ++ ) ; history black stool , vomit blood past 2 month ; unresected primary lesion stomach positive fecal occult blood test ( + ) , ulcerated gastric carcinoma massive alimentary tract bleed risk judge PIs base gastric endoscopy result ; 8 . Abnormal Coagulation ( INR &gt; 1.5、APTT &gt; 1.5 UNL ) , tendency bleed ; 9 . With psychotropic drug abuse history ca n't get rid mental disorder patient ; 10 . Less 4 week last clinical trial ; 11 . According researcher 's judgment , serious disease harm patient safety affect patient complete study ; 12 . Evidence central nervous system ( CNS ) metastasis ; 13 . Pregnant lactating woman ; 14 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>